|
CA2809089C
(en)
|
2010-08-23 |
2018-12-18 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
WO2013008171A1
(en)
*
|
2011-07-11 |
2013-01-17 |
Glenmark Pharmaceuticals S.A. |
Antibodies that bind to ox40 and their uses
|
|
CA2845810C
(en)
*
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
EP3508215A3
(en)
|
2012-12-03 |
2019-10-02 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
EP2964638B1
(en)
|
2013-03-06 |
2017-08-09 |
Astrazeneca AB |
Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
|
|
SG10201708048XA
(en)
|
2013-03-18 |
2017-10-30 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
PT3444271T
(pt)
|
2013-08-08 |
2022-01-05 |
Inst Nat Sante Rech Med |
Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
|
|
CN106029889A
(zh)
*
|
2013-11-22 |
2016-10-12 |
德那翠丝有限公司 |
表达免疫细胞刺激受体激动剂的腺病毒
|
|
WO2015095423A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
EP3322443A1
(en)
*
|
2015-07-13 |
2018-05-23 |
Yeda Research and Development Co. Ltd |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
CA2942245C
(en)
*
|
2014-03-12 |
2021-11-02 |
Yeda Research And Development Co. Ltd. |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
KR20160146747A
(ko)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
|
|
ES2774381T3
(es)
|
2014-04-03 |
2020-07-20 |
Univ Res Inst Inc Augusta |
Métodos para mejorar la eficacia de la respuesta inmune dirigida a tumores
|
|
MD4733C1
(ro)
|
2014-08-19 |
2021-07-31 |
Merck Sharp & Dohme Corp |
Anticorpi anti-TIGIT
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
ES2808153T3
(es)
|
2014-10-31 |
2021-02-25 |
Mereo Biopharma 5 Inc |
Terapia de combinación para tratamiento de enfermedad
|
|
CA2966523A1
(en)
*
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
WO2016073380A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
KR20250005465A
(ko)
*
|
2015-03-03 |
2025-01-09 |
키맵 리미티드 |
항체, 용도 및 방법
|
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
KR20180002653A
(ko)
|
2015-04-07 |
2018-01-08 |
제넨테크, 인크. |
효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
|
|
SG11201708804WA
(en)
|
2015-05-07 |
2017-11-29 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
DK3303396T5
(da)
|
2015-05-29 |
2024-10-07 |
Bristol Myers Squibb Co |
Antistoffer mod ox40 og anvendelser deraf
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
BR112018002436A2
(pt)
*
|
2015-08-04 |
2018-09-18 |
Glaxosmithkline Ip Dev Ltd |
tratamento de combinação de usos de métodos destes
|
|
EP3331917A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
US20180222989A1
(en)
*
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
|
TW201716084A
(zh)
*
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
CN108290936B
(zh)
*
|
2015-08-14 |
2022-07-12 |
默沙东公司 |
抗tigit抗体
|
|
AU2016317915B2
(en)
|
2015-09-01 |
2021-02-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
US10526413B2
(en)
|
2015-10-02 |
2020-01-07 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specific for OX40
|
|
WO2017063162A1
(zh)
*
|
2015-10-15 |
2017-04-20 |
苏州丁孚靶点生物技术有限公司 |
抗ox40抗体及其应用
|
|
PE20181326A1
(es)
|
2015-11-03 |
2018-08-20 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
|
GB201520903D0
(en)
|
2015-11-26 |
2016-01-13 |
Qbd Qs Ip Ltd |
Purification method
|
|
JP2019505476A
(ja)
|
2015-12-01 |
2019-02-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
組合せ処置およびその方法
|
|
MA43389A
(fr)
*
|
2015-12-02 |
2021-05-12 |
Agenus Inc |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
|
CN108883173B
(zh)
*
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
|
CN107849084B
(zh)
|
2015-12-03 |
2021-09-14 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为sting调节剂的环状嘌呤二核苷酸
|
|
AU2016364891A1
(en)
*
|
2015-12-03 |
2018-06-07 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
SG10201601719RA
(en)
|
2016-03-04 |
2017-10-30 |
Agency Science Tech & Res |
Anti-LAG-3 Antibodies
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
JP2019510802A
(ja)
|
2016-04-07 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
タンパク質調節物質として有用な複素環アミド
|
|
PT3440076T
(pt)
|
2016-04-07 |
2022-07-29 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas úteis como modeladores de proteína
|
|
KR20190003699A
(ko)
|
2016-05-05 |
2019-01-09 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
제스트 인핸서 상동체 2 억제제
|
|
SG10201603721TA
(en)
|
2016-05-10 |
2017-12-28 |
Agency Science Tech & Res |
Anti-CTLA-4 Antibodies
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
US20190241573A1
(en)
|
2016-07-20 |
2019-08-08 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
WO2018031258A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
WO2018031400A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
US11279948B2
(en)
|
2016-08-31 |
2022-03-22 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Genetically modified non-human animal with human or chimeric OX40
|
|
CN107815465B
(zh)
|
2016-08-31 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化基因改造动物模型的制备方法及应用
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
US20190343803A1
(en)
|
2016-12-01 |
2019-11-14 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
KR20190090823A
(ko)
*
|
2016-12-01 |
2019-08-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 요법
|
|
BR112019012328A2
(pt)
|
2016-12-15 |
2019-11-19 |
Abbvie Biotherapeutics Inc |
anticorpos anti-ox40 e seus usos
|
|
US20200347143A1
(en)
|
2016-12-19 |
2020-11-05 |
Glenmark Pharmaceuticals S.A. |
Novel tnfr agonists and uses thereof
|
|
MX2019007963A
(es)
|
2017-01-06 |
2019-10-21 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
|
|
US20190375847A1
(en)
|
2017-02-15 |
2019-12-12 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
US20200062735A1
(en)
|
2017-02-27 |
2020-02-27 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors
|
|
CN108623686A
(zh)
|
2017-03-25 |
2018-10-09 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
|
AR112072A1
(es)
|
2017-06-05 |
2019-09-18 |
Iovance Biotherapeutics Inc |
Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
|
|
BR112019025913A2
(pt)
*
|
2017-06-09 |
2020-06-30 |
Glaxosmithkline Intellectual Property Development Limited |
métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira.
|
|
JP2020522556A
(ja)
*
|
2017-06-09 |
2020-07-30 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
AU2018331430A1
(en)
|
2017-09-13 |
2020-03-19 |
Radimmune Therapeutics, Inc. |
Melanin antibodies and uses thereof
|
|
AU2018344902B2
(en)
|
2017-10-05 |
2021-06-03 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING) useful in treating HIV
|
|
CA3077337A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting)
|
|
JP2021501801A
(ja)
|
2017-11-01 |
2021-01-21 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
癌の処置に用いるための免疫刺激アゴニスト抗体
|
|
CR20200251A
(es)
|
2017-11-17 |
2020-07-17 |
Iovance Biotherapeutics Inc |
Expansión de til de aspirados con aguja fina y biopsias por punción
|
|
WO2019106605A1
(en)
|
2017-12-01 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Combination treatment for cancer
|
|
US11142579B2
(en)
|
2017-12-06 |
2021-10-12 |
Sorrento Therapeutics, Inc. |
Variant antibodies that bind OX40
|
|
AU2018394939B2
(en)
|
2017-12-29 |
2022-02-24 |
Ap Biosciences, Inc. |
Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
EP3737743A1
(en)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CN111393529B
(zh)
*
|
2018-01-29 |
2022-02-22 |
康源博创生物科技(北京)有限公司 |
与ox40l非竞争结合的抗ox40抗体
|
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
|
TW202003555A
(zh)
*
|
2018-03-07 |
2020-01-16 |
英商葛蘭素史克智慧財產發展有限公司 |
用於純化重組多肽之方法
|
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
TWI831778B
(zh)
|
2018-05-11 |
2024-02-11 |
澳門商同潤澳門一人有限公司 |
抗ox40的全人抗體及其製備方法和用途
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
BR112020023746A2
(pt)
*
|
2018-05-23 |
2021-02-17 |
Beigene, Ltd. |
anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
US20210277135A1
(en)
|
2018-07-13 |
2021-09-09 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
|
|
EP3827019A1
(en)
|
2018-07-24 |
2021-06-02 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
IL281423B2
(en)
|
2018-09-20 |
2024-08-01 |
Iovance Biotherapeutics Inc |
Expansion of TILS from cryopreserved tumor samples
|
|
TW202035455A
(zh)
*
|
2018-09-26 |
2020-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｏｘ４０抗體、其抗原結合片段及其醫藥用途
|
|
CN120623346A
(zh)
|
2018-10-11 |
2025-09-12 |
因荷布瑞克斯生物科学公司 |
Pd-1单结构域抗体及其治疗组合物
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
JP2022504802A
(ja)
|
2018-10-11 |
2022-01-13 |
インヒブルクス インコーポレイテッド |
５ｔ４シングルドメイン抗体およびその治療組成物
|
|
JP7854297B2
(ja)
|
2018-11-05 |
2026-05-01 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
改良された腫瘍反応性ｔ細胞の選択
|
|
US12611427B2
(en)
|
2018-11-05 |
2026-04-28 |
Iovance Biotherapeutics, Inc. |
Treatment of NSCLC patients refractory for anti-PD-1 antibody
|
|
MY210603A
(en)
|
2018-11-05 |
2025-10-01 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
WO2020096927A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
US20220017629A1
(en)
*
|
2018-11-20 |
2022-01-20 |
Shanghai Pharmaexplorer Co., Ltd. |
Ox40 antibody, preparation method thereof and use thereof
|
|
CA3123392A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
US10442866B1
(en)
*
|
2019-01-23 |
2019-10-15 |
Beijing Mabworks Biotech Co. Ltd |
Antibodies binding OX40 and uses thereof
|
|
BR112021014662A2
(pt)
|
2019-02-01 |
2021-09-21 |
Glaxosmithkline Intellectual Property Development Limited |
Tratamentos de combinação para o câncer que compreendem belantamab mafodotin e um anticorpo anti ox40 e usos e métodos dos mesmos
|
|
US20220177841A1
(en)
|
2019-03-29 |
2022-06-09 |
Myst Therapeutics Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US20220227761A1
(en)
|
2019-05-16 |
2022-07-21 |
Stingthera, Inc. |
Oxoacridinyl acetic acid derivatives and methods of use
|
|
WO2020232378A1
(en)
|
2019-05-16 |
2020-11-19 |
Silicon Swat, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
KR20220016155A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
EP3990494A1
(en)
|
2019-06-26 |
2022-05-04 |
GlaxoSmithKline Intellectual Property Development Limited |
Il1rap binding proteins
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
EP4011389A4
(en)
*
|
2019-08-09 |
2024-09-04 |
Riken |
COMBINED USE OF ARTIFICIAL AUXILIARY VECTOR CELLS AND IMMUNE STIMULANT
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
WO2021058711A2
(en)
|
2019-09-27 |
2021-04-01 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US20230032934A1
(en)
|
2019-11-27 |
2023-02-02 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
IL293471A
(en)
*
|
2019-12-17 |
2022-08-01 |
Amgen Inc |
Dual interleukin-2 / tnf receptor agonist for use in medicine
|
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
EP4077318B1
(en)
|
2019-12-18 |
2025-10-15 |
Ctxt Pty Ltd |
Benzimidazole dimers as modulators of sting
|
|
WO2021143914A1
(zh)
*
|
2020-01-19 |
2021-07-22 |
迈威(上海)生物科技股份有限公司 |
一种激活型抗ox40抗体、生产方法及应用
|
|
JP2023512023A
(ja)
|
2020-01-28 |
2023-03-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
併用療法及びその使用及び方法
|
|
EP4512828A3
(en)
|
2020-02-27 |
2025-05-14 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
CA3176826A1
(en)
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
CA3177413A1
(en)
|
2020-05-04 |
2021-11-11 |
Michelle SIMPSON-ABELSON |
Selection of improved tumor reactive t-cells
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
CN112442121A
(zh)
*
|
2020-08-20 |
2021-03-05 |
山东兴瑞生物科技有限公司 |
Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用
|
|
AU2021334361A1
(en)
|
2020-08-31 |
2023-05-11 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
|
|
CN116368154A
(zh)
|
2020-10-08 |
2023-06-30 |
阿菲姆德股份有限公司 |
三特异性结合剂
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
EP4259164A1
(en)
|
2020-12-11 |
2023-10-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
|
AU2021401302A1
(en)
|
2020-12-17 |
2023-07-06 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
EP4262827A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
US20220233693A1
(en)
|
2020-12-28 |
2022-07-28 |
Bristol-Myers Squibb Company |
Antibody Compositions and Methods of Use Thereof
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
EP4288455A1
(en)
|
2021-02-03 |
2023-12-13 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
CN112957475B
(zh)
*
|
2021-02-04 |
2022-07-22 |
李文峰 |
一种预防和或治疗肿瘤的组合物及应用
|
|
CA3212345A1
(en)
|
2021-03-02 |
2022-09-09 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
|
JP2024512029A
(ja)
|
2021-03-25 |
2024-03-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
|
|
JP2024511831A
(ja)
|
2021-03-31 |
2024-03-15 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質およびそれらの組み合わせ
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
CA3215830A1
(en)
|
2021-04-19 |
2022-10-27 |
Rafael CUBAS |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
AU2022303363A1
(en)
|
2021-06-29 |
2024-01-18 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
JP2024527961A
(ja)
|
2021-07-28 |
2024-07-26 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
|
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
|
US20250000903A1
(en)
|
2021-09-24 |
2025-01-02 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
WO2023077015A2
(en)
|
2021-10-27 |
2023-05-04 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
CA3237410A1
(en)
|
2021-11-10 |
2023-05-19 |
Friedrich Graf Finck VON FINCKENSTEIN |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
CA3243416A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS
|
|
WO2023152116A1
(en)
|
2022-02-08 |
2023-08-17 |
Hookipa Biotech Gmbh |
Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
|
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
JP2025512401A
(ja)
|
2022-04-15 |
2025-04-17 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
|
|
KR20250022071A
(ko)
|
2022-06-02 |
2025-02-14 |
브리스톨-마이어스 스큅 컴퍼니 |
항체 조성물 및 이의 이용 방법
|
|
US20260021181A1
(en)
|
2022-08-01 |
2026-01-22 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
EP4583999A1
(en)
|
2022-09-09 |
2025-07-16 |
Bristol-Myers Squibb Company |
Methods of separating chelator
|
|
IL319568A
(en)
|
2022-09-15 |
2025-05-01 |
Avidicure Ip B V |
Multispecific antigen-binding proteins for NK cell stimulation and their uses
|
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
TW202509071A
(zh)
|
2023-05-12 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
能夠與ｏｘ４０結合之抗體、其變異體及其用途
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
IL326123A
(en)
*
|
2023-07-25 |
2026-03-01 |
Inmagene Pte Ltd |
Treatment methods for alopecia areata and atopic dermatitis
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
TW202540189A
(zh)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
在組合療法中能夠結合ｏｘ４０之抗體
|
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|
|
US12605349B2
(en)
|
2024-09-05 |
2026-04-21 |
Orbus Therapeutics, Inc. |
Methods of treating grade 3 astrocytoma
|